AMRC three-lens brief
Evidence-based stock research on AMRC. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA below 200-day MA (death-cross regime); price below both. · Negative free cash flow last quarterly (-$371.46M).
- 50-day MA below 200-day MA (death-cross regime); price below both.
- Outperforming SPY by 19.2pp over 30 days.
- Analyst mean target $42.70 — 87% above current (10 analysts).
- Negative free cash flow last quarterly (-$371.46M).
AMRC closed at $22.79 (-0.04%) as of 2026-09-11. Market cap: $1.21B. P/E (trailing) 43.0. Price is below the 50-day MA and below the 200-day MA. Positives: outperforming SPY by 19.2pp over 30 days.; analyst mean target $42.70 — 87% above current (10 analysts).. Concerns: 50-day MA below 200-day MA (death-cross regime); price below both.; negative free cash flow last quarterly (-$371.46M).. Last quarter: Revenue $515.46M, net income $9.72M, free cash flow -$371.46M.
Why three lenses on AMRC, not one.
A single reasoning model has blind spots it doesn’t know about. We examine AMRCacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/AMRC" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath AMRC brief"></iframe>